
Economists Are The Only Barrier To A Return To The Gold Standard
At least 66 countries peg their currencies to the dollar. The previous number undercounts the actual number.
Figure that the growth of cryptocurrencies is largely a dollar peg story (think stablecoins), which means even more of the world is pegged to the U.S. dollar. Which is the point.
As Nathan Lewis has long observed, the 'yes, but' arguments against a gold standard are completely bogus. To see why, contemplate the dollar once again.
From 1944 to 1971, the dollar was pegged to gold at 1/35th of a gold ounce and the world's currencies were largely pegged to the dollar. Assuming Treasury secretary Scott Bessent were to announce a plan for substantial currency-price stability by tying the dollar's value to a fixed amount of the constant that is gold, it's no reach to speculate that much of the world would follow such a move by pegging their currencies to gold through their existing dollar pegs.
This rates mention in the aftermath of a recent Monetarium event put on by Confusion Capital in Washington, D.C. The event was titled 'The Debt, the Dollar, and Our Options From Here.' Participants included a few former senators, a billionaire, CEOs, think tank types, etc.
While conversation centered around what to do if and when the national debt leads to a dollar crack-up (my upcoming book, The Deficit Delusion , argues that the crisis narrative is backwards, that the real problem is way too much tax revenue now and in the future), the gold standard only rated mention (with some frequency) insofar as it was described as the one fix that would never happen. This didn't, nor does it ring true.
Economists in particular dismiss the gold notion for obvious, easy-to-discredit reasons. For one, they claim a dollar tied to gold would limit so-called 'money supply.' No, not true. The only limit to money in circulation is production. Money is an effect of production (that's why there's so much in Palo Alto, CA, and so relatively little in El Monte, CA), and it's always where production is.
This would be even truer with a dollar pegged to gold. If anything, dollars circulating would skyrocket to reflect the happy fact that savers would no longer need to hedge their currency exposure in wealth that already exists (think hard assets like land, rare art, housing, and – yes – gold), and would instead feel freer to invest in equities representing wealth that doesn't yet exist . Under such a scenario, production would rapidly increase as would dollars facilitating same. Markets at work.
Still others claim all the debt would make a gold standard a non-starter, that the debt itself has only been possible without a gold standard. Quite the opposite. The national debt is just income streams in dollars months, years and decades in the future. If the dollar were more credible thanks to a gold definition, interest in Treasury income streams would be much greater.
Which brings us to economists. They don't want a gold standard precisely because money with a strict definition via gold would render their raison d'etre anything but. Even allegedly 'free market' economists (see the laughable 'market monetarist' religion within the PhD crowd) see a center planner when they look in the mirror, thus the alleged 'impossibility' of a gold standard. Call the presumed impossibility of a gold standard a full employment act for economists.
The world is pegged to the dollar either implicitly or explicitly. This would only become more viable and growth-oriented if the dollar had a more trusted definition. The barrier to a gold standard is economists rendered even more irrelevant by one, nothing else.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio


Bloomberg
36 minutes ago
- Bloomberg
Barrick Weighs Sale of Gold Mine to Discovery Silver
Barrick Mining Corp. is in advanced talks to sell its last Canadian gold mine to Discovery Silver Corp., according to people familiar with the matter, as the firms seek to capitalize on the soaring price of the precious metal. Discovery Silver is in the final stages of a process Barrick launched in April to sell the Hemlo gold mine in Ontario, the people said, who asked not to be named. There's no certainty the deliberations will lead to a transaction, the people said.

Wall Street Journal
40 minutes ago
- Wall Street Journal
BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results
BlackRock's BLK -5.36%decrease; red down pointing triangle shares tumbled more than 6% Tuesday after the investing giant said a large client pulled money during the second quarter. The investment firm's $5.42 billion in quarterly revenue fell short of analysts' average estimates, driven in part by lower net inflows. A key culprit of the shortfall was a move by a single institutional client in Asia to pull $52 billion from the firm's index funds.